ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Quizartinib Receives Orphan Drug Designation from Japanese MHLW
americanpharmaceuticalreview
September 12, 2018Daiichi Sankyo Company announced quizartinib, an investigational FLT3 inhibitor, has been granted Orphan Drug designation by the Japan Ministry of Health, Labour and Welfare (MHLW) for the treatment of FLT3-mutated acute myeloid leukemia (AML).
Pharma Sources Insight July 2025
